Table 1 Baseline characteristics
Total number of patients | 64 |
|---|---|
Age in years, median (range) | 69 (49–83) |
PSA ng/ml, median (range) | 17 (2,3–281) |
Clinical tumour stage | |
 cT1c | 6 (9%) |
 cT2a | 8 (13%) |
 cT2b | 7 (11%) |
 cT2c | 17 (27%) |
 cT3a | 8 (13%) |
 cT3b | 11 (17%) |
 cT4a | 4 (6%) |
Gleason score | |
 6 | 3 (5%) |
 7aa | 9 (14%) |
 7bb | 8 (13%) |
 8 | 29 (45%) |
 ≥ 9 | 15 (23%) |
Risk stratification | |
 Intermediate risk | 8 (13%) |
 High-risk | 56 (87%) |
ADT use at time of PSMA PET/CT | |
 Yes | 5 (8%) |
 No | 59 (92%) |